Anthony Jarkowski

Company: Bristol Myers Squibb
Job title: Executive Director, Early Development & Program Lead
Seminars:
Exploring the Adjuvant vs. Neoadjuvant Debate 12:30 pm
Understanding Nivolumab with chemotherapy as neoadjuvant treatment Discussing the data for adjuvant vs. neoadjuvant based on disease stage, actionable mutation status and PD-L1 status Delving into the thoughts and future directions of this dynamic conversationRead more
day: Day Two